PharmaTher Holdings Ltd (OTCQB: PHRRF) (CSE: PHRM), is a Canadian company focused on the development and commercialization of medicines derived from ketamine. PharmaTher announced on Wednesday that the U.S. Food and Drug Administration (FDA) has accepted an application to proceed with a Phase 2 clinical trial for an ALS treatment.
According to the press release, “The FDA has accepted an investigator-initiated investigational new drug (“IND”) application to proceed with a Phase 2 clinical trial (the “Study”) evaluating ketamine in the treatment of Amyotrophic Lateral Sclerosis (“ALS”), also known as Lou Gehrig’s disease.”
This designation follows an earlier …
Original Article: benzinga.com